Nubeqa

Overview

darolutamide

antiandrogen

• CYP3A4 substrate
• P-gp substrate
• BCRP inhibitor
• OATP1B1 inhibitor, strong
• OATP1B3 inhibitor, strong
• CYP3A4 inducer, weak
• lowers seizure threshold

Contraindicated

• elagolix
Nubeqa (darolutamide)

+

elagolix

1 interaction

Contraindicated

darolutamide + elagolix

contraindicated: combo may incr. levels of both drugs, risk of adverse effects (P-gp-mediated transport inhibited, hepatic transport inhibited)

• grazoprevir
Nubeqa (darolutamide)

+

grazoprevir

1 interaction

Contraindicated

darolutamide + grazoprevir

contraindicated: combo may incr. or decr. grazoprevir levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metab. induced)

• ranolazine
Nubeqa (darolutamide)

+

ranolazine

1 interaction

Contraindicated

darolutamide + ranolazine

contraindicated: combo may decr. ranolazine levels, efficacy; may incr. darolutamide levels, risk of adverse effects (hepatic metab. induced; P-gp-mediated transport inhibited)

Avoid/Use Alternative

• aldesleukin
Nubeqa (darolutamide)

+

aldesleukin

1 interaction

Avoid/Use Alternative

darolutamide + aldesleukin

avoid combo: combo may incr. risk of seizures (additive effects)

• alpelisib
Nubeqa (darolutamide)

+

alpelisib

1 interaction

Avoid/Use Alternative

darolutamide + alpelisib

use alternative: combo may incr. alpelisib levels, risk of adverse effects (BCRP-mediated transport possibly inhibited)

• amifampridine
Nubeqa (darolutamide)

+

amifampridine

1 interaction

Avoid/Use Alternative

darolutamide + amifampridine

consider alternative: combo may incr. risk of seizures (additive effects)

• apalutamide
Nubeqa (darolutamide)

+

apalutamide

1 interaction

Avoid/Use Alternative

darolutamide + apalutamide

avoid combo: combo may decr. darolutamide levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• atazanavir
Nubeqa (darolutamide)

+

atazanavir

1 interaction

Avoid/Use Alternative

darolutamide + atazanavir

avoid combo: combo may decr. atazanavir levels, efficacy; may incr. darolutamide levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited)

• atogepant
Nubeqa (darolutamide)

+

atogepant

1 interaction

Avoid/Use Alternative

darolutamide + atogepant

avoid combo: combo may incr. or decr. atogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited; hepatic metab. induced)

• atrasentan
Nubeqa (darolutamide)

+

atrasentan

1 interaction

Avoid/Use Alternative

darolutamide + atrasentan

avoid combo: combo may incr. atrasentan levels, risk of adverse effects (hepatic transport inhibited)

• bosentan
Nubeqa (darolutamide)

+

bosentan

1 interaction

Avoid/Use Alternative

darolutamide + bosentan

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy; may incr. bosentan levels, risk of adverse effects (hepatic metab. induced; hepatic transport inhibited)

• brincidofovir
Nubeqa (darolutamide)

+

brincidofovir

1 interaction

Avoid/Use Alternative

darolutamide + brincidofovir

consider alternative or monitor LFTs, GI toxicity sx; give brincidofovir at least 3h before darolutamide: combo may incr. brincidofovir levels, risk of hepatotoxicity, GI toxicity, other adverse effects (hepatic transport inhibited)

• butalbital
Nubeqa (darolutamide)

+

butalbital

1 interaction

Avoid/Use Alternative

darolutamide + butalbital

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• carbamazepine
Nubeqa (darolutamide)

+

carbamazepine

1 interaction

Avoid/Use Alternative

darolutamide + carbamazepine

avoid combo: combo may decr. levels of both drugs, efficacy; may alter seizure control (hepatic metab. induced, P-gp-mediated transport induced; antagonistic effects, darolutamide may decr. seizure threshold)

• cenobamate
Nubeqa (darolutamide)

+

cenobamate

1 interaction

Avoid/Use Alternative

darolutamide + cenobamate

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, darolutamide may decr. seizure threshold)

• cladribine oral
Nubeqa (darolutamide)

+

cladribine oral

1 interaction

Avoid/Use Alternative

darolutamide + cladribine oral

use alternative or monitor CBC: combo may incr. cladribine levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited)

• codeine
Nubeqa (darolutamide)

+

codeine

1 interaction

Avoid/Use Alternative

darolutamide + codeine

use alternative or monitor withdrawal sx: combo may decr. codeine and active metabolite morphine levels, efficacy (hepatic metab. induced, may decr. production of morphine)

• dabrafenib
Nubeqa (darolutamide)

+

dabrafenib

1 interaction

Avoid/Use Alternative

darolutamide + dabrafenib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• danshen
Nubeqa (darolutamide)

+

danshen

1 interaction

Avoid/Use Alternative

darolutamide + danshen

avoid combo if also combined w/ a moderate or strong CYP3A4 inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (P-gp-mediated transport induced)

• desogestrel (contraceptive)
Nubeqa (darolutamide)

+

desogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + desogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. desogestrel levels, contraceptive efficacy (hepatic metab. induced)

• dicloxacillin
Nubeqa (darolutamide)

+

dicloxacillin

1 interaction

Avoid/Use Alternative

darolutamide + dicloxacillin

avoid combo if also combined w/ a moderate or strong CYP3A4 inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (P-gp-mediated transport induced)

• dienogest (contraceptive)
Nubeqa (darolutamide)

+

dienogest (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + dienogest (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. dienogest levels, contraceptive efficacy (hepatic metab. induced)

• dolutegravir
Nubeqa (darolutamide)

+

dolutegravir

1 interaction

Avoid/Use Alternative

darolutamide + dolutegravir

avoid combo: combo may decr. dolutegravir levels, efficacy (hepatic metab. induced)

• drospirenone (contraceptive)
Nubeqa (darolutamide)

+

drospirenone (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + drospirenone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. drospirenone levels, contraceptive efficacy (hepatic metab. induced)

• efavirenz
Nubeqa (darolutamide)

+

efavirenz

1 interaction

Avoid/Use Alternative

darolutamide + efavirenz

avoid combo: combo may decr. darolutamide levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• encorafenib
Nubeqa (darolutamide)

+

encorafenib

1 interaction

Avoid/Use Alternative

darolutamide + encorafenib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• enzalutamide
Nubeqa (darolutamide)

+

enzalutamide

1 interaction

Avoid/Use Alternative

darolutamide + enzalutamide

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

• estradiol (contraceptive)
Nubeqa (darolutamide)

+

estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. estradiol levels, contraceptive efficacy (hepatic metab. induced)

• ethinyl estradiol (contraceptive)
Nubeqa (darolutamide)

+

ethinyl estradiol (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + ethinyl estradiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. ethinyl estradiol levels, contraceptive efficacy (hepatic metab. induced)

• ethynodiol (contraceptive)
Nubeqa (darolutamide)

+

ethynodiol (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + ethynodiol (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. ethynodiol and active metabolite levels, contraceptive efficacy (hepatic metab. induced)

• etonogestrel (contraceptive)
Nubeqa (darolutamide)

+

etonogestrel (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + etonogestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. etonogestrel levels, contraceptive efficacy (hepatic metab. induced)

• etravirine
Nubeqa (darolutamide)

+

etravirine

1 interaction

Avoid/Use Alternative

darolutamide + etravirine

avoid combo if also combined w/ P-gp inducer; if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. induced, P-gp-mediated transport inhibited)

• fentanyl
Nubeqa (darolutamide)

+

fentanyl

1 interaction

Avoid/Use Alternative

darolutamide + fentanyl

use alternative or monitor withdrawal sx: combo may decr. fentanyl levels, efficacy (hepatic metab. induced)

• fexinidazole
Nubeqa (darolutamide)

+

fexinidazole

1 interaction

Avoid/Use Alternative

darolutamide + fexinidazole

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• fosamprenavir
Nubeqa (darolutamide)

+

fosamprenavir

1 interaction

Avoid/Use Alternative

darolutamide + fosamprenavir

avoid combo: combo may decr. amprenavir levels, efficacy (hepatic metab. induced)

• fosphenytoin
Nubeqa (darolutamide)

+

fosphenytoin

1 interaction

Avoid/Use Alternative

darolutamide + fosphenytoin

avoid combo: combo may decr. darolutamide levels, efficacy; may alter seizure control (hepatic metab. induced, P-gp-mediated transport induced; antagonistic effects, darolutamide may decr. seizure threshold)

• iohexol
Nubeqa (darolutamide)

+

iohexol

1 interaction

Avoid/Use Alternative

darolutamide + iohexol

avoid combo if intrathecal iohexol use: combo may incr. risk of seizures (additive effects)

• ivosidenib
Nubeqa (darolutamide)

+

ivosidenib

1 interaction

Avoid/Use Alternative

darolutamide + ivosidenib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• levonorgestrel (contraceptive)
Nubeqa (darolutamide)

+

levonorgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + levonorgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. levonorgestrel levels, contraceptive efficacy (hepatic metab. induced)

• levonorgestrel (post-coital contraceptive)
Nubeqa (darolutamide)

+

levonorgestrel (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + levonorgestrel (post-coital contraceptive)

consider alternative: combo may decr. levonorgestrel levels, post-coital contraceptive efficacy (hepatic metab. induced)

• lopinavir/ritonavir
Nubeqa (darolutamide)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

darolutamide + lopinavir/ ritonavir

avoid combo: combo may decr. lopinavir/ritonavir levels, efficacy; may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. induced; hepatic metab. altered, P-gp-mediated transport inhibited)

• lorlatinib
Nubeqa (darolutamide)

+

lorlatinib

1 interaction

Avoid/Use Alternative

darolutamide + lorlatinib

avoid combo: combo may decr. levels of both drugs, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• lovastatin
Nubeqa (darolutamide)

+

lovastatin

1 interaction

Avoid/Use Alternative

darolutamide + lovastatin

use alternative or monitor CK, myopathy sx: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited)

• lumacaftor/ivacaftor
Nubeqa (darolutamide)

+

lumacaftor/ ivacaftor

1 interaction

Avoid/Use Alternative

darolutamide + lumacaftor/ ivacaftor

avoid combo: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. induced, P-gp-mediated transport possibly altered)

• lumateperone
Nubeqa (darolutamide)

+

lumateperone

1 interaction

Avoid/Use Alternative

darolutamide + lumateperone

avoid combo: combo may decr. lumateperone levels, efficacy (hepatic metab. induced)

• mavacamten
Nubeqa (darolutamide)

+

mavacamten

1 interaction

Avoid/Use Alternative

darolutamide + mavacamten

avoid combo if also combined w/ P-gp inducer; otherwise, consider alternative or monitor cardiac fxn: combo may decr. levels, efficacy of both drugs (hepatic metab. induced)

• medroxyprogesterone (contraceptive)
Nubeqa (darolutamide)

+

medroxyprogesterone (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + medroxyprogesterone (contraceptive)

use additional non-hormonal or alternative contraception: combo may decr. medroxyprogesterone levels, contraceptive efficacy (hepatic metab. induced)

• meperidine
Nubeqa (darolutamide)

+

meperidine

1 interaction

Avoid/Use Alternative

darolutamide + meperidine

use alternative or monitor for withdrawal sx: combo may decr. meperidine levels, efficacy; may incr. normeperidine levels, risk of neurotoxicity (hepatic metab. induced, incr. toxic metabolite formation)

• mitapivat
Nubeqa (darolutamide)

+

mitapivat

1 interaction

Avoid/Use Alternative

darolutamide + mitapivat

avoid combo if also combined w/ P-gp inducer; otherwise, monitor Hgb: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy; may decr. mitapivat levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• mitotane
Nubeqa (darolutamide)

+

mitotane

1 interaction

Avoid/Use Alternative

darolutamide + mitotane

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• modafinil
Nubeqa (darolutamide)

+

modafinil

1 interaction

Avoid/Use Alternative

darolutamide + modafinil

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• nafcillin
Nubeqa (darolutamide)

+

nafcillin

1 interaction

Avoid/Use Alternative

darolutamide + nafcillin

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• norelgestromin (contraceptive)
Nubeqa (darolutamide)

+

norelgestromin (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + norelgestromin (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. norelgestromin levels, contraceptive efficacy (hepatic metab. induced)

• norethindrone (contraceptive)
Nubeqa (darolutamide)

+

norethindrone (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + norethindrone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. norethindrone levels, contraceptive efficacy (hepatic metab. induced)

• norgestimate (contraceptive)
Nubeqa (darolutamide)

+

norgestimate (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + norgestimate (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. norgestimate and active metabolites levels, contraceptive efficacy (hepatic metab. induced)

• norgestrel (contraceptive)
Nubeqa (darolutamide)

+

norgestrel (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + norgestrel (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. norgestrel levels, contraceptive efficacy (hepatic metab. induced)

• oliceridine
Nubeqa (darolutamide)

+

oliceridine

1 interaction

Avoid/Use Alternative

darolutamide + oliceridine

use alternative or monitor withdrawal sx; consider oliceridine dose adjustment: combo may decr. oliceridine levels, efficacy (hepatic metab. induced)

• oxycodone
Nubeqa (darolutamide)

+

oxycodone

1 interaction

Avoid/Use Alternative

darolutamide + oxycodone

use alternative or monitor withdrawal sx: combo may decr. oxycodone levels, efficacy (hepatic metab. induced)

• pacritinib
Nubeqa (darolutamide)

+

pacritinib

1 interaction

Avoid/Use Alternative

darolutamide + pacritinib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• pazopanib
Nubeqa (darolutamide)

+

pazopanib

1 interaction

Avoid/Use Alternative

darolutamide + pazopanib

avoid combo: combo may incr. pazopanib levels, risk of QT prolongation, cardiac arrhythmias, other adverse effects (BCRP-mediated transport inhibited)

• pentobarbital
Nubeqa (darolutamide)

+

pentobarbital

1 interaction

Avoid/Use Alternative

darolutamide + pentobarbital

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• pexidartinib
Nubeqa (darolutamide)

+

pexidartinib

1 interaction

Avoid/Use Alternative

darolutamide + pexidartinib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. darolutamide levels, efficacy (hepatic metab. induced)

• phenobarbital
Nubeqa (darolutamide)

+

phenobarbital

1 interaction

Avoid/Use Alternative

darolutamide + phenobarbital

avoid combo: combo may decr. darolutamide levels, efficacy; may alter seizure control (hepatic metab. induced, P-gp-mediated transport possibly induced; antagonistic effects, darolutamide may decr. seizure threshold)

• phenytoin
Nubeqa (darolutamide)

+

phenytoin

1 interaction

Avoid/Use Alternative

darolutamide + phenytoin

avoid combo: combo may decr. darolutamide levels, efficacy; may alter seizure control (hepatic metab. induced, P-gp-mediated transport induced; antagonistic effects, darolutamide may decr. seizure threshold)

• pitavastatin
Nubeqa (darolutamide)

+

pitavastatin

1 interaction

Avoid/Use Alternative

darolutamide + pitavastatin

use alternative or monitor CK, myopathy sx: combo may incr. pitavastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• primidone
Nubeqa (darolutamide)

+

primidone

1 interaction

Avoid/Use Alternative

darolutamide + primidone

avoid combo: combo may decr. darolutamide levels, efficacy; may alter seizure control (hepatic metab. induced, P-gp-mediated transport possibly induced; antagonistic effects, darolutamide may decr. seizure threshold)

• red yeast rice
Nubeqa (darolutamide)

+

red yeast rice

1 interaction

Avoid/Use Alternative

darolutamide + red yeast rice

use alternative or monitor CK, myopathy sx w/ large amounts of red yeast rice: combo may incr. lovastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, red yeast rice contains varying amounts of lovastatin)

• repotrectinib
Nubeqa (darolutamide)

+

repotrectinib

1 interaction

Avoid/Use Alternative

darolutamide + repotrectinib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may decr. levels of both drugs, efficacy (hepatic metab. induced)

• resmetirom
Nubeqa (darolutamide)

+

resmetirom

1 interaction

Avoid/Use Alternative

darolutamide + resmetirom

avoid combo: combo may incr. resmetirom levels, risk of adverse effects (hepatic transport possibly inhibited)

• revefenacin inhaled
Nubeqa (darolutamide)

+

revefenacin inhaled

1 interaction

Avoid/Use Alternative

darolutamide + revefenacin inhaled

use alternative: combo may incr. revefanacin active metabolite levels, risk of adverse effects (hepatic transport inhibited)

• rifabutin
Nubeqa (darolutamide)

+

rifabutin

1 interaction

Avoid/Use Alternative

darolutamide + rifabutin

avoid combo: combo may decr. darolutamide levels, efficacy (hepatic metab. induced, P-gp-mediated transport possibly induced)

• rifampin
Nubeqa (darolutamide)

+

rifampin

1 interaction

Avoid/Use Alternative

darolutamide + rifampin

avoid combo: combo may decr. darolutamide levels, efficacy; may incr. rifampin levels, risk of adverse effects (hepatic metab. induced, P-gp-mediated transport induced; hepatic transport inhibited)

• rifapentine
Nubeqa (darolutamide)

+

rifapentine

1 interaction

Avoid/Use Alternative

darolutamide + rifapentine

avoid combo: combo may decr. darolutamide levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• segesterone (contraceptive)
Nubeqa (darolutamide)

+

segesterone (contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + segesterone (contraceptive)

use additional non-hormonal or alternative contraception during and x28 days after darolutamide tx: combo may decr. segesterone levels, contraceptive efficacy (hepatic metab. induced)

• sotorasib
Nubeqa (darolutamide)

+

sotorasib

1 interaction

Avoid/Use Alternative

darolutamide + sotorasib

avoid combo if also combined w/ P-gp inducer; otherwise, caution advised: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited, hepatic metab. induced)

• St. John's wort
Nubeqa (darolutamide)

+

St. John's wort

1 interaction

Avoid/Use Alternative

darolutamide + St. John's wort

avoid combo: combo may decr. darolutamide levels, efficacy (hepatic metab. induced, P-gp-mediated transport induced)

• tenofovir disoproxil
Nubeqa (darolutamide)

+

tenofovir disoproxil

1 interaction

Avoid/Use Alternative

darolutamide + tenofovir disoproxil

use alternative or monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut BCRP-mediated transport inhibited)

• tipranavir
Nubeqa (darolutamide)

+

tipranavir

1 interaction

Avoid/Use Alternative

darolutamide + tipranavir

avoid combo if also combined w/ a moderate or strong CYP3A4 inducer; otherwise, caution advised: combo may decr. tipranavir levels, efficacy; may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. induced; hepatic metab. inhibited, P-gp-mediated transport altered)

• topotecan
Nubeqa (darolutamide)

+

topotecan

1 interaction

Avoid/Use Alternative

darolutamide + topotecan

avoid combo w/ oral topotecan: combo may incr. topotecan levels, risk of serious infection, myelosuppression, other adverse effects (gut BCRP-mediated transport inhibited)

• tramadol
Nubeqa (darolutamide)

+

tramadol

1 interaction

Avoid/Use Alternative

darolutamide + tramadol

use alternative or monitor withdrawal sx: combo may decr. tramadol levels, efficacy; may incr. risk of seizures (hepatic metab. induced; additive effects)

• turmeric
Nubeqa (darolutamide)

+

turmeric

1 interaction

Avoid/Use Alternative

darolutamide + turmeric

avoid combo w/ oral turmeric: combo may incr. or decr. darolutamide levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport altered)

• ulipristal (post-coital contraceptive)
Nubeqa (darolutamide)

+

ulipristal (post-coital contraceptive)

1 interaction

Avoid/Use Alternative

darolutamide + ulipristal (post-coital contraceptive)

avoid combo: combo may decr. ulipristal levels, post-coital contraceptive efficacy (hepatic metab. induced)

• voxilaprevir
Nubeqa (darolutamide)

+

voxilaprevir

1 interaction

Avoid/Use Alternative

darolutamide + voxilaprevir

avoid combo: combo may incr. levels of both drugs, risk of adverse effects; may decr. voxilaprevir levels, efficacy (gut P-gp-mediated transport inhibited, hepatic transport inhibited; hepatic metab. induced)

• zavegepant
Nubeqa (darolutamide)

+

zavegepant

1 interaction

Avoid/Use Alternative

darolutamide + zavegepant

avoid combo: combo may incr. zavegepant levels, risk of adverse effects (hepatic transport inhibited)

• zuranolone
Nubeqa (darolutamide)

+

zuranolone

1 interaction

Avoid/Use Alternative

darolutamide + zuranolone

avoid combo: combo may decr. zuranolone levels, efficacy (hepatic metab. induced)

Monitor/Modify Tx

• amlodipine
Nubeqa (darolutamide)

+

amlodipine

1 interaction

Monitor/Modify Tx

darolutamide + amlodipine

monitor BP: combo may decr. (lev)amlodipine levels, efficacy (hepatic metab. induced)

• atorvastatin
Nubeqa (darolutamide)

+

atorvastatin

1 interaction

Monitor/Modify Tx

darolutamide + atorvastatin

monitor CK, myopathy sx: combo may incr. or decr. atorvastatin levels, incr. risk of myopathy, rhabdomyolysis, other adverse effects or decr. efficacy (BCRP-mediated transport inhibited, hepatic transport inhibited, hepatic metab. induced)

• buprenorphine
Nubeqa (darolutamide)

+

buprenorphine

1 interaction

Monitor/Modify Tx

darolutamide + buprenorphine

monitor withdrawal sx: combo may decr. buprenorphine levels, efficacy (hepatic metab. induced)

• bupropion
Nubeqa (darolutamide)

+

bupropion

1 interaction

Monitor/Modify Tx

darolutamide + bupropion

consider lower bupropion doses: combo may incr. risk of seizures (additive effects)

• cyclophosphamide
Nubeqa (darolutamide)

+

cyclophosphamide

1 interaction

Monitor/Modify Tx

darolutamide + cyclophosphamide

monitor CBC, renal, cardiac fxn: combo may incr. cyclophosphamide active metabolite levels, risk of serious infection, myelosuppression, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metab. possibly induced, incr. active metabolite formation)

• cyclosporine
Nubeqa (darolutamide)

+

cyclosporine

1 interaction

Monitor/Modify Tx

darolutamide + cyclosporine

monitor cyclosporine levels: combo may incr. darolutamide levels, risk of adverse effects; may decr. cyclosporine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• diltiazem
Nubeqa (darolutamide)

+

diltiazem

1 interaction

Monitor/Modify Tx

darolutamide + diltiazem

monitor BP, HR: combo may incr. darolutamide levels, risk of adverse effects; may decr. diltiazem levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• disopyramide
Nubeqa (darolutamide)

+

disopyramide

1 interaction

Monitor/Modify Tx

darolutamide + disopyramide

monitor disopyramide levels: combo may decr. disopyramide levels, efficacy (hepatic metab. induced)

• eluxadoline
Nubeqa (darolutamide)

+

eluxadoline

1 interaction

Monitor/Modify Tx

darolutamide + eluxadoline

decr. eluxadoline dose to 75 mg bid: combo may incr. eluxadoline levels, risk of adverse effects (hepatic transport inhibited)

• erdafitinib
Nubeqa (darolutamide)

+

erdafitinib

1 interaction

Monitor/Modify Tx

darolutamide + erdafitinib

separate admin. by at least 6h: combo may incr. darolutamide levels, risk of adverse effects; may decr. erdafitinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• erythromycin
Nubeqa (darolutamide)

+

erythromycin

1 interaction

Monitor/Modify Tx

darolutamide + erythromycin

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• everolimus
Nubeqa (darolutamide)

+

everolimus

1 interaction

Monitor/Modify Tx

darolutamide + everolimus

BREAST CA, PNET, RENAL CELL CA, RENAL ANGIOMYOLIPOMA W/ TSC: caution advised; TSC-ASSOC. SEGA or TSC-ASSOC. PARTIAL-ONSET SEIZURES, TRANSPLANT: monitor everolimus levels: combo may decr. everolimus levels, efficacy (hepatic metab. induced)

• fluvastatin
Nubeqa (darolutamide)

+

fluvastatin

1 interaction

Monitor/Modify Tx

darolutamide + fluvastatin

monitor CK, myopathy sx: combo may incr. fluvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited, hepatic transport inhibited)

• glyburide
Nubeqa (darolutamide)

+

glyburide

1 interaction

Monitor/Modify Tx

darolutamide + glyburide

monitor glucose: combo may incr. glyburide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• ifosfamide
Nubeqa (darolutamide)

+

ifosfamide

1 interaction

Monitor/Modify Tx

darolutamide + ifosfamide

monitor CBC, renal, cardiac fxn; consider ifosfamide dose adjustment: combo may incr. ifosfamide active and toxic metabolite levels, risk of myelosuppression, serious infection, encephalopathy, nephrotoxicity, cardiotoxicity, other adverse effects (hepatic metab. induced, incr. metabolite formation)

• imatinib
Nubeqa (darolutamide)

+

imatinib

1 interaction

Monitor/Modify Tx

darolutamide + imatinib

monitor CBC: combo may incr. or decr. imatinib levels, incr. risk of myelosuppression, other adverse effects or decr. efficacy (BCRP-mediated transport inhibited, hepatic metab. induced)

• iopamidol
Nubeqa (darolutamide)

+

iopamidol

1 interaction

Monitor/Modify Tx

darolutamide + iopamidol

caution advised if intrathecal iopamidol use; consider holding darolutamide at least 48h before and at least 24h after intrathecal iopamidol: combo may incr. risk of seizures (additive effects)

• irinotecan
Nubeqa (darolutamide)

+

irinotecan

1 interaction

Monitor/Modify Tx

darolutamide + irinotecan

monitor CBC: combo may incr. or decr. irinotecan and active metabolite levels, incr. risk of serious infection, myelosuppression, other adverse effects or decr. efficacy (BCRP-mediated transport inhibited, hepatic transport inhibited, hepatic metab. induced)

• isradipine
Nubeqa (darolutamide)

+

isradipine

1 interaction

Monitor/Modify Tx

darolutamide + isradipine

monitor BP: combo may decr. isradipine levels, efficacy (hepatic metab. induced)

• ketoconazole
Nubeqa (darolutamide)

+

ketoconazole

1 interaction

Monitor/Modify Tx

darolutamide + ketoconazole

monitor for breakthrough fungal infection: combo may incr. darolutamide levels, risk of adverse effects; may decr. ketoconazole levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• lapatinib
Nubeqa (darolutamide)

+

lapatinib

1 interaction

Monitor/Modify Tx

darolutamide + lapatinib

monitor ECG: combo may incr. darolutamide levels, risk of adverse effects; may incr. or decr. lapatinib levels, incr. risk of QT prolongation, cardiac arrhythmias, other adverse effects or decr. efficacy (P-gp-mediated transport inhibited; BCRP-mediated transport inhibited, hepatic metab. induced)

• maraviroc
Nubeqa (darolutamide)

+

maraviroc

1 interaction

Monitor/Modify Tx

darolutamide + maraviroc

consider maraviroc dose adjustment: combo may incr. or decr. maraviroc levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metab. induced)

• methotrexate
Nubeqa (darolutamide)

+

methotrexate

1 interaction

Monitor/Modify Tx

darolutamide + methotrexate

monitor CBC, renal fxn: combo may incr. methotrexate levels, risk of serious infection, myelosuppression, nephrotoxicity, other adverse effects (BCRP-mediated transport inhibited, hepatic transport inhibited)

• mitoxantrone
Nubeqa (darolutamide)

+

mitoxantrone

1 interaction

Monitor/Modify Tx

darolutamide + mitoxantrone

monitor CBC, cardiac fxn, incl. LVEF: combo may incr. mitoxantrone levels, risk of serious infection, myelosuppression, cardiotoxicity, other adverse effects (BCRP-mediated transport inhibited)

• momelotinib
Nubeqa (darolutamide)

+

momelotinib

1 interaction

Monitor/Modify Tx

darolutamide + momelotinib

monitor CBC, bleeding s/sx: combo may incr. momelotinib levels, risk of serious infection, myelosuppression, other adverse effects (hepatic transport inhibited)

• nateglinide
Nubeqa (darolutamide)

+

nateglinide

1 interaction

Monitor/Modify Tx

darolutamide + nateglinide

monitor glucose: combo may incr. nateglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• nicardipine
Nubeqa (darolutamide)

+

nicardipine

1 interaction

Monitor/Modify Tx

darolutamide + nicardipine

monitor BP: combo may decr. nicardipine levels, efficacy (hepatic metab. induced)

• nimodipine
Nubeqa (darolutamide)

+

nimodipine

1 interaction

Monitor/Modify Tx

darolutamide + nimodipine

monitor BP: combo may decr. nimodipine levels, efficacy (hepatic metab. induced)

• nisoldipine
Nubeqa (darolutamide)

+

nisoldipine

1 interaction

Monitor/Modify Tx

darolutamide + nisoldipine

monitor BP: combo may decr. nisoldipine levels, efficacy (hepatic metab. induced)

• perampanel
Nubeqa (darolutamide)

+

perampanel

1 interaction

Monitor/Modify Tx

darolutamide + perampanel

consider incr. perampanel start dose to 4 mg/day: combo may decr. perampanel levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, darolutamide may decr. seizure threshold)

• pravastatin
Nubeqa (darolutamide)

+

pravastatin

1 interaction

Monitor/Modify Tx

darolutamide + pravastatin

monitor CK, myopathy sx: combo may incr. pravastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (hepatic transport inhibited, BCRP-mediated transport inhibited)

• quinidine (antiarrhythmic)
Nubeqa (darolutamide)

+

quinidine (antiarrhythmic)

1 interaction

Monitor/Modify Tx

darolutamide + quinidine (antiarrhythmic)

monitor quinidine levels: combo may incr. darolutamide levels, risk of adverse effects; may decr. quinidine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• repaglinide
Nubeqa (darolutamide)

+

repaglinide

1 interaction

Monitor/Modify Tx

darolutamide + repaglinide

monitor glucose: combo may incr. repaglinide levels, risk of hypoglycemia, other adverse effects (hepatic transport inhibited)

• riociguat
Nubeqa (darolutamide)

+

riociguat

1 interaction

Monitor/Modify Tx

darolutamide + riociguat

consider decr. riociguat start dose to 0.5 mg PO tid; monitor BP: combo may incr. riociguat levels, risk of severe hypotension, other adverse effects (BCRP-mediated transport inhibited)

• rosuvastatin
Nubeqa (darolutamide)

+

rosuvastatin

1 interaction

Monitor/Modify Tx

darolutamide + rosuvastatin

monitor CK, myopathy sx; max rosuvastatin dose 5 mg/day: combo may incr. rosuvastatin levels, risk of myopathy, rhabdomyolysis, other adverse effects (BCRP-mediated transport inhibited, hepatic transport inhibited)

• simvastatin
Nubeqa (darolutamide)

+

simvastatin

1 interaction

Monitor/Modify Tx

darolutamide + simvastatin

monitor CK, myopathy sx: combo may incr. or decr. simvastatin levels, incr. risk of myopathy, rhabdomyolysis, other adverse effects or decr. efficacy (hepatic transport inhibited, BCRP-mediated transport inhibited, hepatic metab. induced)

• sirolimus
Nubeqa (darolutamide)

+

sirolimus

1 interaction

Monitor/Modify Tx

darolutamide + sirolimus

monitor sirolimus levels: combo may decr. sirolimus levels, efficacy (hepatic metab. induced)

• tacrolimus
Nubeqa (darolutamide)

+

tacrolimus

1 interaction

Monitor/Modify Tx

darolutamide + tacrolimus

monitor tacrolimus levels: combo may incr. darolutamide levels, risk of adverse effects; may decr. tacrolimus levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• talazoparib
Nubeqa (darolutamide)

+

talazoparib

1 interaction

Monitor/Modify Tx

darolutamide + talazoparib

monitor CBC: combo may incr. talazoparib levels, risk of myelosuppression, other adverse effects (BCRP-mediated transport inhibited)

• tenofovir alafenamide
Nubeqa (darolutamide)

+

tenofovir alafenamide

1 interaction

Monitor/Modify Tx

darolutamide + tenofovir alafenamide

if tenofovir alafenamide not admin. w/ cobicistat, monitor renal fxn: combo may incr. tenofovir levels, risk of nephrotoxicity, other adverse effects (gut BCRP-mediated transport inhibited)

• tiagabine
Nubeqa (darolutamide)

+

tiagabine

1 interaction

Monitor/Modify Tx

darolutamide + tiagabine

consider tiagabine dose adjustment if not on concurrent enzyme-inducing AEDs; titrate tiagabine dose to effect if already on enzyme-inducing AEDs: combo may decr. tiagabine levels, efficacy; may alter seizure control (hepatic metab. induced; further induction possible if on concurrent enzyme-inducing AEDs; antagonistic effects, darolutamide may decr. seizure threshold)

• ubrogepant
Nubeqa (darolutamide)

+

ubrogepant

1 interaction

Monitor/Modify Tx

darolutamide + ubrogepant

consider ubrogepant dose adjustment: combo may incr. or decr. ubrogepant levels, incr. risk of adverse effects or decr. efficacy (hepatic metab. induced; BCRP-mediated transport inhibited)

• valsartan
Nubeqa (darolutamide)

+

valsartan

1 interaction

Monitor/Modify Tx

darolutamide + valsartan

monitor potassium: combo may incr. valsartan levels, risk of hyperkalemia, other adverse effects (hepatic transport inhibited)

• venetoclax
Nubeqa (darolutamide)

+

venetoclax

1 interaction

Monitor/Modify Tx

darolutamide + venetoclax

give darolutamide at least 6h before venetoclax: combo may incr. darolutamide levels, risk of adverse effects; may decr. venetoclax levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• vimseltinib
Nubeqa (darolutamide)

+

vimseltinib

1 interaction

Monitor/Modify Tx

darolutamide + vimseltinib

if also combined w/ strong CYP3A4 inhibitor, caution advised; give vimseltinib at least 4h before darolutamide: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• voriconazole
Nubeqa (darolutamide)

+

voriconazole

1 interaction

Monitor/Modify Tx

darolutamide + voriconazole

monitor for breakthrough fungal infection: combo may incr. darolutamide levels, risk of adverse effects; may decr. voriconazole levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• warfarin
Nubeqa (darolutamide)

+

warfarin

1 interaction

Monitor/Modify Tx

darolutamide + warfarin

monitor INR: combo may decr. warfarin levels, efficacy (hepatic metab. induced)

Caution Advised

• abemaciclib
Nubeqa (darolutamide)

+

abemaciclib

1 interaction

Caution Advised

darolutamide + abemaciclib

caution advised: combo may decr. abemaciclib levels, efficacy (hepatic metab. induced)

• abrocitinib
Nubeqa (darolutamide)

+

abrocitinib

1 interaction

Caution Advised

darolutamide + abrocitinib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• acalabrutinib
Nubeqa (darolutamide)

+

acalabrutinib

1 interaction

Caution Advised

darolutamide + acalabrutinib

caution advised: combo may decr. acalabrutinib levels, efficacy (hepatic metab. induced)

• acetazolamide
Nubeqa (darolutamide)

+

acetazolamide

1 interaction

Caution Advised

darolutamide + acetazolamide

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• adagrasib
Nubeqa (darolutamide)

+

adagrasib

1 interaction

Caution Advised

darolutamide + adagrasib

caution advised: combo may incr. darolutamide levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• alfentanil
Nubeqa (darolutamide)

+

alfentanil

1 interaction

Caution Advised

darolutamide + alfentanil

caution advised: combo may decr. alfentanil levels, efficacy (hepatic metab. induced)

• alprazolam
Nubeqa (darolutamide)

+

alprazolam

1 interaction

Caution Advised

darolutamide + alprazolam

caution advised: combo may decr. alprazolam levels, efficacy (hepatic metab. induced)

• amiodarone
Nubeqa (darolutamide)

+

amiodarone

1 interaction

Caution Advised

darolutamide + amiodarone

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. amiodarone levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• aprepitant
Nubeqa (darolutamide)

+

aprepitant

1 interaction

Caution Advised

darolutamide + aprepitant

caution advised: combo may decr. aprepitant levels, efficacy (hepatic metab. induced)

• artemether/lumefantrine
Nubeqa (darolutamide)

+

artemether/ lumefantrine

1 interaction

Caution Advised

darolutamide + artemether/ lumefantrine

caution advised: combo may decr. artemether/lumefantrine levels, efficacy (hepatic metab. induced)

• asciminib
Nubeqa (darolutamide)

+

asciminib

1 interaction

Caution Advised

darolutamide + asciminib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• avacopan
Nubeqa (darolutamide)

+

avacopan

1 interaction

Caution Advised

darolutamide + avacopan

caution advised: combo may decr. avacopan levels, efficacy (hepatic metab. induced)

• avapritinib
Nubeqa (darolutamide)

+

avapritinib

1 interaction

Caution Advised

darolutamide + avapritinib

caution advised: combo may decr. avapritinib levels, efficacy (hepatic metab. induced)

• axitinib
Nubeqa (darolutamide)

+

axitinib

1 interaction

Caution Advised

darolutamide + axitinib

caution advised: combo may decr. axitinib levels, efficacy (hepatic metab. induced)

• azithromycin
Nubeqa (darolutamide)

+

azithromycin

1 interaction

Caution Advised

darolutamide + azithromycin

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• belumosudil
Nubeqa (darolutamide)

+

belumosudil

1 interaction

Caution Advised

darolutamide + belumosudil

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• berotralstat
Nubeqa (darolutamide)

+

berotralstat

1 interaction

Caution Advised

darolutamide + berotralstat

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• bictegravir
Nubeqa (darolutamide)

+

bictegravir

1 interaction

Caution Advised

darolutamide + bictegravir

caution advised if also combined w/ UGT1A1 inducer: combo may decr. bictegravir levels, efficacy (hepatic metab. induced)

• bisoprolol
Nubeqa (darolutamide)

+

bisoprolol

1 interaction

Caution Advised

darolutamide + bisoprolol

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• bosutinib
Nubeqa (darolutamide)

+

bosutinib

1 interaction

Caution Advised

darolutamide + bosutinib

caution advised: combo may decr. bosutinib levels, efficacy (hepatic metab. induced)

• brigatinib
Nubeqa (darolutamide)

+

brigatinib

1 interaction

Caution Advised

darolutamide + brigatinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. brigatinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• brivaracetam
Nubeqa (darolutamide)

+

brivaracetam

1 interaction

Caution Advised

darolutamide + brivaracetam

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• budesonide
Nubeqa (darolutamide)

+

budesonide

1 interaction

Caution Advised

darolutamide + budesonide

caution advised: combo may decr. budesonide levels, efficacy (hepatic metab. induced)

• buspirone
Nubeqa (darolutamide)

+

buspirone

1 interaction

Caution Advised

darolutamide + buspirone

caution advised: combo may decr. buspirone levels, efficacy (hepatic metab. induced)

• busulfan
Nubeqa (darolutamide)

+

busulfan

1 interaction

Caution Advised

darolutamide + busulfan

caution advised: combo may incr. risk of seizures (additive effects)

• cabozantinib
Nubeqa (darolutamide)

+

cabozantinib

1 interaction

Caution Advised

darolutamide + cabozantinib

caution advised: combo may decr. cabozantinib levels, efficacy (hepatic metab. induced)

• canagliflozin
Nubeqa (darolutamide)

+

canagliflozin

1 interaction

Caution Advised

darolutamide + canagliflozin

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• cannabidiol
Nubeqa (darolutamide)

+

cannabidiol

1 interaction

Caution Advised

darolutamide + cannabidiol

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may alter seizure control (gut P-gp-mediated transport inhibited; antagonistic effects, darolutamide may decr. seizure threshold)

• capivasertib
Nubeqa (darolutamide)

+

capivasertib

1 interaction

Caution Advised

darolutamide + capivasertib

caution advised: combo may decr. capivasertib levels, efficacy (hepatic metab. induced)

• capmatinib
Nubeqa (darolutamide)

+

capmatinib

1 interaction

Caution Advised

darolutamide + capmatinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. capmatinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• captopril
Nubeqa (darolutamide)

+

captopril

1 interaction

Caution Advised

darolutamide + captopril

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• carvedilol
Nubeqa (darolutamide)

+

carvedilol

1 interaction

Caution Advised

darolutamide + carvedilol

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• ceritinib
Nubeqa (darolutamide)

+

ceritinib

1 interaction

Caution Advised

darolutamide + ceritinib

if also combined w/ P-gp inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (hepatic metab. inhibited)

• chlorambucil
Nubeqa (darolutamide)

+

chlorambucil

1 interaction

Caution Advised

darolutamide + chlorambucil

caution advised: combo may incr. risk of seizures (additive effects)

• chloramphenicol
Nubeqa (darolutamide)

+

chloramphenicol

1 interaction

Caution Advised

darolutamide + chloramphenicol

if also combined w/ P-gp inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (hepatic metab. inhibited)

• cimetidine
Nubeqa (darolutamide)

+

cimetidine

1 interaction

Caution Advised

darolutamide + cimetidine

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• clarithromycin
Nubeqa (darolutamide)

+

clarithromycin

1 interaction

Caution Advised

darolutamide + clarithromycin

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. clarithromycin levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• clobazam
Nubeqa (darolutamide)

+

clobazam

1 interaction

Caution Advised

darolutamide + clobazam

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• clomipramine
Nubeqa (darolutamide)

+

clomipramine

1 interaction

Caution Advised

darolutamide + clomipramine

caution advised: combo may incr. risk of seizures (additive effects)

• clonazepam
Nubeqa (darolutamide)

+

clonazepam

1 interaction

Caution Advised

darolutamide + clonazepam

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• clorazepate
Nubeqa (darolutamide)

+

clorazepate

1 interaction

Caution Advised

darolutamide + clorazepate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• cobicistat
Nubeqa (darolutamide)

+

cobicistat

1 interaction

Caution Advised

darolutamide + cobicistat

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. cobicistat levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• cobimetinib
Nubeqa (darolutamide)

+

cobimetinib

1 interaction

Caution Advised

darolutamide + cobimetinib

caution advised: combo may decr. cobimetinib levels, efficacy (hepatic metab. induced)

• conivaptan
Nubeqa (darolutamide)

+

conivaptan

1 interaction

Caution Advised

darolutamide + conivaptan

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• crizotinib
Nubeqa (darolutamide)

+

crizotinib

1 interaction

Caution Advised

darolutamide + crizotinib

caution advised: combo may decr. crizotinib levels, efficacy (hepatic metab. induced)

• danicopan
Nubeqa (darolutamide)

+

danicopan

1 interaction

Caution Advised

darolutamide + danicopan

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• daridorexant
Nubeqa (darolutamide)

+

daridorexant

1 interaction

Caution Advised

darolutamide + daridorexant

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. daridorexant levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• darunavir
Nubeqa (darolutamide)

+

darunavir

1 interaction

Caution Advised

darolutamide + darunavir

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. darunavir levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• dasatinib
Nubeqa (darolutamide)

+

dasatinib

1 interaction

Caution Advised

darolutamide + dasatinib

caution advised: combo may decr. dasatinib levels, efficacy (hepatic metab. induced)

• defactinib
Nubeqa (darolutamide)

+

defactinib

1 interaction

Caution Advised

darolutamide + defactinib

caution advised: combo may decr. defactinib levels, efficacy (hepatic metab. induced)

• deflazacort
Nubeqa (darolutamide)

+

deflazacort

1 interaction

Caution Advised

darolutamide + deflazacort

caution advised: combo may decr. deflazacort active metabolite levels, efficacy (hepatic metab. induced)

• diazepam
Nubeqa (darolutamide)

+

diazepam

1 interaction

Caution Advised

darolutamide + diazepam

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• diosmin
Nubeqa (darolutamide)

+

diosmin

1 interaction

Caution Advised

darolutamide + diosmin

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• doravirine
Nubeqa (darolutamide)

+

doravirine

1 interaction

Caution Advised

darolutamide + doravirine

caution advised: combo may decr. doravirine levels, efficacy (hepatic metab. induced)

• dronedarone
Nubeqa (darolutamide)

+

dronedarone

1 interaction

Caution Advised

darolutamide + dronedarone

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. dronedarone levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• drospirenone (hormone replacement)
Nubeqa (darolutamide)

+

drospirenone (hormone replacement)

1 interaction

Caution Advised

darolutamide + drospirenone (hormone replacement)

caution advised: combo may decr. drospirenone levels, efficacy (hepatic metab. induced)

• elacestrant
Nubeqa (darolutamide)

+

elacestrant

1 interaction

Caution Advised

darolutamide + elacestrant

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. elacestrant levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• elbasvir
Nubeqa (darolutamide)

+

elbasvir

1 interaction

Caution Advised

darolutamide + elbasvir

caution advised: combo may decr. elbasvir levels, efficacy (hepatic metab. induced)

• elexacaftor/tezacaftor/ivacaftor
Nubeqa (darolutamide)

+

elexacaftor/ tezacaftor/ ivacaftor

1 interaction

Caution Advised

darolutamide + elexacaftor/ tezacaftor/ ivacaftor

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. elexacaftor/tezacaftor/ivacaftor levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• eliglustat
Nubeqa (darolutamide)

+

eliglustat

1 interaction

Caution Advised

darolutamide + eliglustat

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. eliglustat levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• elvitegravir
Nubeqa (darolutamide)

+

elvitegravir

1 interaction

Caution Advised

darolutamide + elvitegravir

caution advised: combo may decr. elvitegravir levels, efficacy (hepatic metab. induced)

• enasidenib
Nubeqa (darolutamide)

+

enasidenib

1 interaction

Caution Advised

darolutamide + enasidenib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• entrectinib
Nubeqa (darolutamide)

+

entrectinib

1 interaction

Caution Advised

darolutamide + entrectinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. entrectinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• erlotinib
Nubeqa (darolutamide)

+

erlotinib

1 interaction

Caution Advised

darolutamide + erlotinib

caution advised: combo may decr. erlotinib levels, efficacy (hepatic metab. induced)

• eslicarbazepine acetate
Nubeqa (darolutamide)

+

eslicarbazepine acetate

1 interaction

Caution Advised

darolutamide + eslicarbazepine acetate

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• ethosuximide
Nubeqa (darolutamide)

+

ethosuximide

1 interaction

Caution Advised

darolutamide + ethosuximide

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• fedratinib
Nubeqa (darolutamide)

+

fedratinib

1 interaction

Caution Advised

darolutamide + fedratinib

caution advised: combo may decr. fedratinib levels, efficacy (hepatic metab. induced)

• felbamate
Nubeqa (darolutamide)

+

felbamate

1 interaction

Caution Advised

darolutamide + felbamate

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• felodipine
Nubeqa (darolutamide)

+

felodipine

1 interaction

Caution Advised

darolutamide + felodipine

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. felodipine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• fenfluramine
Nubeqa (darolutamide)

+

fenfluramine

1 interaction

Caution Advised

darolutamide + fenfluramine

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• finerenone
Nubeqa (darolutamide)

+

finerenone

1 interaction

Caution Advised

darolutamide + finerenone

caution advised: combo may decr. finerenone levels, efficacy (hepatic metab. induced)

• flibanserin
Nubeqa (darolutamide)

+

flibanserin

1 interaction

Caution Advised

darolutamide + flibanserin

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• fluvoxamine
Nubeqa (darolutamide)

+

fluvoxamine

1 interaction

Caution Advised

darolutamide + fluvoxamine

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• fosaprepitant
Nubeqa (darolutamide)

+

fosaprepitant

1 interaction

Caution Advised

darolutamide + fosaprepitant

caution advised: combo may decr. aprepitant levels, efficacy (hepatic metab. induced)

• fostamatinib
Nubeqa (darolutamide)

+

fostamatinib

1 interaction

Caution Advised

darolutamide + fostamatinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. fostamatinib active metabolite levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• fruquintinib
Nubeqa (darolutamide)

+

fruquintinib

1 interaction

Caution Advised

darolutamide + fruquintinib

caution advised: combo may decr. fruquintinib levels, efficacy (hepatic metab. induced)

• futibatinib
Nubeqa (darolutamide)

+

futibatinib

1 interaction

Caution Advised

darolutamide + futibatinib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• gabapentin
Nubeqa (darolutamide)

+

gabapentin

1 interaction

Caution Advised

darolutamide + gabapentin

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• ganaxolone
Nubeqa (darolutamide)

+

ganaxolone

1 interaction

Caution Advised

darolutamide + ganaxolone

caution advised: combo may decr. ganaxolone levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, darolutamide may decr. seizure threshold)

• gepirone
Nubeqa (darolutamide)

+

gepirone

1 interaction

Caution Advised

darolutamide + gepirone

caution advised: combo may decr. gepirone levels, efficacy (hepatic metab. induced)

• gilteritinib
Nubeqa (darolutamide)

+

gilteritinib

1 interaction

Caution Advised

darolutamide + gilteritinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. gilteritinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• ginkgo
Nubeqa (darolutamide)

+

ginkgo

1 interaction

Caution Advised

darolutamide + ginkgo

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may incr. risk of seizures (P-gp-mediated transport inhibited; additive effects)

• glasdegib
Nubeqa (darolutamide)

+

glasdegib

1 interaction

Caution Advised

darolutamide + glasdegib

caution advised: combo may decr. glasdegib levels, efficacy (hepatic metab. induced)

• glecaprevir
Nubeqa (darolutamide)

+

glecaprevir

1 interaction

Caution Advised

darolutamide + glecaprevir

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may incr. or decr. glecaprevir levels, incr. risk of adverse effects or decr. efficacy (P-gp-mediated transport inhibited; BCRP-mediated transport inhibited, hepatic transport inhibited; hepatic metab. induced)

• guanfacine
Nubeqa (darolutamide)

+

guanfacine

1 interaction

Caution Advised

darolutamide + guanfacine

caution advised: combo may decr. guanfacine levels, efficacy (hepatic metab. induced)

• haloperidol
Nubeqa (darolutamide)

+

haloperidol

1 interaction

Caution Advised

darolutamide + haloperidol

caution advised: combo may decr. haloperidol levels, efficacy (hepatic metab. induced)

• hydrocortisone
Nubeqa (darolutamide)

+

hydrocortisone

1 interaction

Caution Advised

darolutamide + hydrocortisone

caution advised: combo may decr. hydrocortisone levels, efficacy (hepatic metab. induced)

• hydroxychloroquine
Nubeqa (darolutamide)

+

hydroxychloroquine

1 interaction

Caution Advised

darolutamide + hydroxychloroquine

caution advised: combo may incr. risk of seizures (additive effects)

• ibrutinib
Nubeqa (darolutamide)

+

ibrutinib

1 interaction

Caution Advised

darolutamide + ibrutinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. ibrutinib levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• idelalisib
Nubeqa (darolutamide)

+

idelalisib

1 interaction

Caution Advised

darolutamide + idelalisib

caution advised: combo may incr. darolutamide levels, risk of adverse effects (hepatic metab. inhibited)

• indomethacin
Nubeqa (darolutamide)

+

indomethacin

1 interaction

Caution Advised

darolutamide + indomethacin

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• infigratinib
Nubeqa (darolutamide)

+

infigratinib

1 interaction

Caution Advised

darolutamide + infigratinib

caution advised: combo may decr. infigratinib levels, efficacy (hepatic metab. induced)

• isavuconazonium
Nubeqa (darolutamide)

+

isavuconazonium

1 interaction

Caution Advised

darolutamide + isavuconazonium

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. isavuconazole levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• istradefylline
Nubeqa (darolutamide)

+

istradefylline

1 interaction

Caution Advised

darolutamide + istradefylline

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. istradefylline levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• itraconazole
Nubeqa (darolutamide)

+

itraconazole

1 interaction

Caution Advised

darolutamide + itraconazole

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. itraconazole levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• ivacaftor
Nubeqa (darolutamide)

+

ivacaftor

1 interaction

Caution Advised

darolutamide + ivacaftor

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. ivacaftor levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• lacosamide
Nubeqa (darolutamide)

+

lacosamide

1 interaction

Caution Advised

darolutamide + lacosamide

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• lamotrigine
Nubeqa (darolutamide)

+

lamotrigine

1 interaction

Caution Advised

darolutamide + lamotrigine

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• larotrectinib
Nubeqa (darolutamide)

+

larotrectinib

1 interaction

Caution Advised

darolutamide + larotrectinib

caution advised: combo may decr. larotrectinib levels, efficacy (hepatic metab. induced)

• lasmiditan
Nubeqa (darolutamide)

+

lasmiditan

1 interaction

Caution Advised

darolutamide + lasmiditan

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• lazertinib
Nubeqa (darolutamide)

+

lazertinib

1 interaction

Caution Advised

darolutamide + lazertinib

caution advised: combo may decr. lazertinib levels, efficacy (hepatic metab. induced)

• ledipasvir
Nubeqa (darolutamide)

+

ledipasvir

1 interaction

Caution Advised

darolutamide + ledipasvir

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• lefamulin
Nubeqa (darolutamide)

+

lefamulin

1 interaction

Caution Advised

darolutamide + lefamulin

caution advised w/ oral lefamulin: combo may decr. lefamulin levels, efficacy (hepatic metab. induced)

• lenacapavir
Nubeqa (darolutamide)

+

lenacapavir

1 interaction

Caution Advised

darolutamide + lenacapavir

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. lenacapavir levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• leniolisib
Nubeqa (darolutamide)

+

leniolisib

1 interaction

Caution Advised

darolutamide + leniolisib

caution advised: combo may decr. leniolisib levels, efficacy (hepatic metab. induced)

• letermovir
Nubeqa (darolutamide)

+

letermovir

1 interaction

Caution Advised

darolutamide + letermovir

caution advised: combo may incr. or decr. letermovir levels, incr. risk of adverse effects or decr. efficacy (hepatic transport inhibited, hepatic metab. induced)

• levacetylleucine
Nubeqa (darolutamide)

+

levacetylleucine

1 interaction

Caution Advised

darolutamide + levacetylleucine

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• levetiracetam
Nubeqa (darolutamide)

+

levetiracetam

1 interaction

Caution Advised

darolutamide + levetiracetam

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• levoketoconazole
Nubeqa (darolutamide)

+

levoketoconazole

1 interaction

Caution Advised

darolutamide + levoketoconazole

caution advised: combo may decr. levoketoconazole levels, efficacy; may incr. darolutamide levels, risk of adverse effects (hepatic metab. induced; hepatic metab. inhibited, P-gp-mediated transport inhibited)

• levonorgestrel intrauterine device (contraceptive)
Nubeqa (darolutamide)

+

levonorgestrel intrauterine device (contraceptive)

1 interaction

Caution Advised

darolutamide + levonorgestrel intrauterine device (contraceptive)

caution advised: combo may decr. hormonal contraceptive levels, efficacy (hepatic metab. induced)

• lindane topical
Nubeqa (darolutamide)

+

lindane topical

1 interaction

Caution Advised

darolutamide + lindane topical

caution advised: combo may incr. risk of seizures (additive effects)

• lomitapide
Nubeqa (darolutamide)

+

lomitapide

1 interaction

Caution Advised

darolutamide + lomitapide

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• lonafarnib
Nubeqa (darolutamide)

+

lonafarnib

1 interaction

Caution Advised

darolutamide + lonafarnib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. lonafarnib levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• lorazepam
Nubeqa (darolutamide)

+

lorazepam

1 interaction

Caution Advised

darolutamide + lorazepam

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• lurasidone
Nubeqa (darolutamide)

+

lurasidone

1 interaction

Caution Advised

darolutamide + lurasidone

caution advised: combo may decr. lurasidone levels, efficacy (hepatic metab. induced)

• macitentan
Nubeqa (darolutamide)

+

macitentan

1 interaction

Caution Advised

darolutamide + macitentan

caution advised: combo may decr. macitentan levels, efficacy (hepatic metab. induced)

• magnesium citrate
Nubeqa (darolutamide)

+

magnesium citrate

1 interaction

Caution Advised

darolutamide + magnesium citrate

caution advised, especially if magnesium citrate bowel prep use: combo may incr. risk of seizures (additive effects)

• maribavir
Nubeqa (darolutamide)

+

maribavir

1 interaction

Caution Advised

darolutamide + maribavir

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• mavorixafor
Nubeqa (darolutamide)

+

mavorixafor

1 interaction

Caution Advised

darolutamide + mavorixafor

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• meropenem
Nubeqa (darolutamide)

+

meropenem

1 interaction

Caution Advised

darolutamide + meropenem

caution advised: combo may decr. darolutamide levels, efficacy (P-gp-mediated transport possibly induced)

• methadone
Nubeqa (darolutamide)

+

methadone

1 interaction

Caution Advised

darolutamide + methadone

caution advised: combo may decr. methadone levels, efficacy (hepatic metab. induced)

• methsuximide
Nubeqa (darolutamide)

+

methsuximide

1 interaction

Caution Advised

darolutamide + methsuximide

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• midazolam
Nubeqa (darolutamide)

+

midazolam

1 interaction

Caution Advised

darolutamide + midazolam

caution advised w/ oral midazolam; other midazolam routes OK, caution advised if seizure disorder use: combo may decr. midazolam levels, efficacy; may alter seizure control (hepatic metab. induced; antagonistic effects, darolutamide may decr. seizure threshold)

• midostaurin
Nubeqa (darolutamide)

+

midostaurin

1 interaction

Caution Advised

darolutamide + midostaurin

caution advised: combo may decr. midostaurin levels, efficacy (hepatic metab. induced)

• mifepristone
Nubeqa (darolutamide)

+

mifepristone

1 interaction

Caution Advised

darolutamide + mifepristone

caution advised during and x14 days after daily mifepristone use: combo may incr. darolutamide levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• milk thistle
Nubeqa (darolutamide)

+

milk thistle

1 interaction

Caution Advised

darolutamide + milk thistle

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• mirabegron
Nubeqa (darolutamide)

+

mirabegron

1 interaction

Caution Advised

darolutamide + mirabegron

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• mobocertinib
Nubeqa (darolutamide)

+

mobocertinib

1 interaction

Caution Advised

darolutamide + mobocertinib

caution advised: combo may decr. mobocertinib levels, efficacy (hepatic metab. induced)

• naldemedine
Nubeqa (darolutamide)

+

naldemedine

1 interaction

Caution Advised

darolutamide + naldemedine

caution advised: combo may decr. naldemedine levels, efficacy (hepatic metab. induced)

• naloxegol
Nubeqa (darolutamide)

+

naloxegol

1 interaction

Caution Advised

darolutamide + naloxegol

caution advised: combo may decr. naloxegol levels, efficacy (hepatic metab. induced)

• naproxen
Nubeqa (darolutamide)

+

naproxen

1 interaction

Caution Advised

darolutamide + naproxen

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• nefazodone
Nubeqa (darolutamide)

+

nefazodone

1 interaction

Caution Advised

darolutamide + nefazodone

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. nefazodone levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• nelfinavir
Nubeqa (darolutamide)

+

nelfinavir

1 interaction

Caution Advised

darolutamide + nelfinavir

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. nelfinavir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• neratinib
Nubeqa (darolutamide)

+

neratinib

1 interaction

Caution Advised

darolutamide + neratinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. neratinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• netupitant
Nubeqa (darolutamide)

+

netupitant

1 interaction

Caution Advised

darolutamide + netupitant

caution advised: combo may decr. netupitant levels, efficacy (hepatic metab. induced)

• nevirapine
Nubeqa (darolutamide)

+

nevirapine

1 interaction

Caution Advised

darolutamide + nevirapine

caution advised: combo may decr. nevirapine levels, efficacy (hepatic metab. induced)

• nifedipine
Nubeqa (darolutamide)

+

nifedipine

1 interaction

Caution Advised

darolutamide + nifedipine

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. nifedipine levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• nilotinib
Nubeqa (darolutamide)

+

nilotinib

1 interaction

Caution Advised

darolutamide + nilotinib

caution advised: combo may decr. nilotinib levels, efficacy (hepatic metab. induced)

• nirmatrelvir
Nubeqa (darolutamide)

+

nirmatrelvir

1 interaction

Caution Advised

darolutamide + nirmatrelvir

caution advised: combo may decr. nirmatrelvir levels, efficacy (hepatic metab. induced)

• nirogacestat
Nubeqa (darolutamide)

+

nirogacestat

1 interaction

Caution Advised

darolutamide + nirogacestat

caution advised: combo may decr. nirogacestat levels, efficacy (hepatic metab. induced)

• olaparib
Nubeqa (darolutamide)

+

olaparib

1 interaction

Caution Advised

darolutamide + olaparib

caution advised: combo may decr. olaparib levels, efficacy (hepatic metab. induced)

• olutasidenib
Nubeqa (darolutamide)

+

olutasidenib

1 interaction

Caution Advised

darolutamide + olutasidenib

caution advised: combo may decr. olutasidenib levels, efficacy (hepatic metab. induced)

• osimertinib
Nubeqa (darolutamide)

+

osimertinib

1 interaction

Caution Advised

darolutamide + osimertinib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• oxcarbazepine
Nubeqa (darolutamide)

+

oxcarbazepine

1 interaction

Caution Advised

darolutamide + oxcarbazepine

caution advised: combo may decr. darolutamide levels, efficacy; may alter seizure control (P-gp-mediated transport possibly induced; antagonistic effects, darolutamide may decr. seizure threshold)

• palbociclib
Nubeqa (darolutamide)

+

palbociclib

1 interaction

Caution Advised

darolutamide + palbociclib

caution advised: combo may decr. palbociclib levels, efficacy (hepatic metab. induced)

• paroxetine
Nubeqa (darolutamide)

+

paroxetine

1 interaction

Caution Advised

darolutamide + paroxetine

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• pemigatinib
Nubeqa (darolutamide)

+

pemigatinib

1 interaction

Caution Advised

darolutamide + pemigatinib

caution advised: combo may decr. pemigatinib levels, efficacy (hepatic metab. induced)

• pibrentasvir
Nubeqa (darolutamide)

+

pibrentasvir

1 interaction

Caution Advised

darolutamide + pibrentasvir

caution advised: combo may incr. levels of both drugs, risk of adverse effects (BCRP-mediated transport inhibited, P-gp-mediated transport inhibited)

• pimavanserin
Nubeqa (darolutamide)

+

pimavanserin

1 interaction

Caution Advised

darolutamide + pimavanserin

caution advised: combo may decr. pimavanserin levels, efficacy (hepatic metab. induced)

• pirtobrutinib
Nubeqa (darolutamide)

+

pirtobrutinib

1 interaction

Caution Advised

darolutamide + pirtobrutinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. pirtobrutinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• polyethylene glycol
Nubeqa (darolutamide)

+

polyethylene glycol

1 interaction

Caution Advised

darolutamide + polyethylene glycol

caution advised, especially if polyethylene glycol bowel prep use: combo may incr. risk of seizures (additive effects)

• polyethylene glycol/electrolytes
Nubeqa (darolutamide)

+

polyethylene glycol/ electrolytes

1 interaction

Caution Advised

darolutamide + polyethylene glycol/ electrolytes

caution advised: combo may incr. risk of seizures (additive effects)

• ponatinib
Nubeqa (darolutamide)

+

ponatinib

1 interaction

Caution Advised

darolutamide + ponatinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. ponatinib levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• posaconazole
Nubeqa (darolutamide)

+

posaconazole

1 interaction

Caution Advised

darolutamide + posaconazole

caution advised: combo may incr. darolutamide levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• praziquantel
Nubeqa (darolutamide)

+

praziquantel

1 interaction

Caution Advised

darolutamide + praziquantel

caution advised: combo may decr. praziquantel levels, efficacy (hepatic metab. induced)

• pregabalin
Nubeqa (darolutamide)

+

pregabalin

1 interaction

Caution Advised

darolutamide + pregabalin

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• pretomanid
Nubeqa (darolutamide)

+

pretomanid

1 interaction

Caution Advised

darolutamide + pretomanid

caution advised: combo may decr. pretomanid levels, efficacy; may incr. darolutamide levels, risk of adverse effects (hepatic metab. induced; P-gp-mediated transport possibly inhibited)

• promethazine
Nubeqa (darolutamide)

+

promethazine

1 interaction

Caution Advised

darolutamide + promethazine

caution advised: combo may incr. risk of seizures (additive effects)

• propafenone
Nubeqa (darolutamide)

+

propafenone

1 interaction

Caution Advised

darolutamide + propafenone

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• quercetin
Nubeqa (darolutamide)

+

quercetin

1 interaction

Caution Advised

darolutamide + quercetin

caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• quetiapine
Nubeqa (darolutamide)

+

quetiapine

1 interaction

Caution Advised

darolutamide + quetiapine

caution advised: combo may decr. quetiapine levels, efficacy (hepatic metab. induced)

• quinidine (CYP2D6 inhibitor)
Nubeqa (darolutamide)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Caution Advised

darolutamide + quinidine (CYP2D6 inhibitor)

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• quinine
Nubeqa (darolutamide)

+

quinine

1 interaction

Caution Advised

darolutamide + quinine

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. quinine levels, efficacy; may incr. risk of seizures (P-gp-mediated transport inhibited; hepatic metab. induced; additive effects)

• quizartinib
Nubeqa (darolutamide)

+

quizartinib

1 interaction

Caution Advised

darolutamide + quizartinib

caution advised: combo may decr. quizartinib levels, efficacy (hepatic metab. induced)

• ribociclib
Nubeqa (darolutamide)

+

ribociclib

1 interaction

Caution Advised

darolutamide + ribociclib

if also combined w/ P-gp inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. ribociclib levels, efficacy (hepatic metab. inhibited; hepatic metab. induced)

• rilpivirine
Nubeqa (darolutamide)

+

rilpivirine

1 interaction

Caution Advised

darolutamide + rilpivirine

caution advised: combo may decr. rilpivirine levels, efficacy (hepatic metab. induced)

• ripretinib
Nubeqa (darolutamide)

+

ripretinib

1 interaction

Caution Advised

darolutamide + ripretinib

caution advised: combo may decr. ripretinib and active metabolite levels, efficacy (hepatic metab. induced)

• ritonavir
Nubeqa (darolutamide)

+

ritonavir

1 interaction

Caution Advised

darolutamide + ritonavir

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. ritonavir levels, efficacy (hepatic metab. inhibited, P-gp-mediated transport inhibited; hepatic metab. induced)

• roflumilast
Nubeqa (darolutamide)

+

roflumilast

1 interaction

Caution Advised

darolutamide + roflumilast

caution advised: combo may decr. roflumilast levels, efficacy (hepatic metab. induced)

• rolapitant
Nubeqa (darolutamide)

+

rolapitant

1 interaction

Caution Advised

darolutamide + rolapitant

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. rolapitant levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• rucaparib
Nubeqa (darolutamide)

+

rucaparib

1 interaction

Caution Advised

darolutamide + rucaparib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• rufinamide
Nubeqa (darolutamide)

+

rufinamide

1 interaction

Caution Advised

darolutamide + rufinamide

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• samidorphan
Nubeqa (darolutamide)

+

samidorphan

1 interaction

Caution Advised

darolutamide + samidorphan

caution advised: combo may decr. samidorphan levels, efficacy (hepatic metab. induced)

• sarecycline
Nubeqa (darolutamide)

+

sarecycline

1 interaction

Caution Advised

darolutamide + sarecycline

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• seladelpar
Nubeqa (darolutamide)

+

seladelpar

1 interaction

Caution Advised

darolutamide + seladelpar

caution advised: combo may incr. seladelpar levels, risk of adverse effects (BCRP-mediated transport inhibited)

• selpercatinib
Nubeqa (darolutamide)

+

selpercatinib

1 interaction

Caution Advised

darolutamide + selpercatinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. selpercatinib levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• selumetinib
Nubeqa (darolutamide)

+

selumetinib

1 interaction

Caution Advised

darolutamide + selumetinib

caution advised: combo may decr. selumetinib levels, efficacy (hepatic metab. induced)

• sildenafil
Nubeqa (darolutamide)

+

sildenafil

1 interaction

Caution Advised

darolutamide + sildenafil

caution advised: combo may decr. sildenafil levels, efficacy (hepatic metab. induced)

• sirolimus albumin-bound
Nubeqa (darolutamide)

+

sirolimus albumin-bound

1 interaction

Caution Advised

darolutamide + sirolimus albumin-bound

caution advised: combo may decr. sirolimus albumin-bound levels, efficacy (hepatic metab. induced)

• sodium picosulfate
Nubeqa (darolutamide)

+

sodium picosulfate

1 interaction

Caution Advised

darolutamide + sodium picosulfate

caution advised: combo may incr. risk of seizures (additive effects)

• sonidegib
Nubeqa (darolutamide)

+

sonidegib

1 interaction

Caution Advised

darolutamide + sonidegib

caution advised: combo may decr. sonidegib levels, efficacy (hepatic metab. induced)

• sorafenib
Nubeqa (darolutamide)

+

sorafenib

1 interaction

Caution Advised

darolutamide + sorafenib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• sotagliflozin
Nubeqa (darolutamide)

+

sotagliflozin

1 interaction

Caution Advised

darolutamide + sotagliflozin

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• sparsentan
Nubeqa (darolutamide)

+

sparsentan

1 interaction

Caution Advised

darolutamide + sparsentan

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport possibly inhibited)

• stiripentol
Nubeqa (darolutamide)

+

stiripentol

1 interaction

Caution Advised

darolutamide + stiripentol

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may alter seizure control (P-gp-mediated transport inhibited; antagonistic effects, darolutamide may decr. seizure threshold)

• sulfasalazine
Nubeqa (darolutamide)

+

sulfasalazine

1 interaction

Caution Advised

darolutamide + sulfasalazine

caution advised: combo may incr. sulfasalazine levels, risk of adverse effects; may decr. IBD tx efficacy (gut BCRP-mediated transport inhibited)

• sulfate bowel prep
Nubeqa (darolutamide)

+

sulfate bowel prep

1 interaction

Caution Advised

darolutamide + sulfate bowel prep

caution advised: combo may incr. risk of seizures (additive effects)

• suvorexant
Nubeqa (darolutamide)

+

suvorexant

1 interaction

Caution Advised

darolutamide + suvorexant

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (gut P-gp-mediated transport inhibited)

• suzetrigine
Nubeqa (darolutamide)

+

suzetrigine

1 interaction

Caution Advised

darolutamide + suzetrigine

caution advised: combo may decr. suzetrigine and active metabolite levels, efficacy (hepatic metab. induced)

• tadalafil
Nubeqa (darolutamide)

+

tadalafil

1 interaction

Caution Advised

darolutamide + tadalafil

caution advised: combo may decr. tadalafil levels, efficacy (hepatic metab. induced)

• tamoxifen
Nubeqa (darolutamide)

+

tamoxifen

1 interaction

Caution Advised

darolutamide + tamoxifen

caution advised: combo may decr. tamoxifen and active metabolite levels, efficacy (hepatic metab. induced)

• tasimelteon
Nubeqa (darolutamide)

+

tasimelteon

1 interaction

Caution Advised

darolutamide + tasimelteon

caution advised: combo may decr. tasimelteon levels, efficacy (hepatic metab. induced)

• tazemetostat
Nubeqa (darolutamide)

+

tazemetostat

1 interaction

Caution Advised

darolutamide + tazemetostat

caution advised: combo may decr. tazemetostat levels, efficacy (hepatic metab. induced)

• telmisartan
Nubeqa (darolutamide)

+

telmisartan

1 interaction

Caution Advised

darolutamide + telmisartan

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• temsirolimus
Nubeqa (darolutamide)

+

temsirolimus

1 interaction

Caution Advised

darolutamide + temsirolimus

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. temsirolimus and active metabolite sirolimus levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• tepotinib
Nubeqa (darolutamide)

+

tepotinib

1 interaction

Caution Advised

darolutamide + tepotinib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• tezacaftor/ivacaftor
Nubeqa (darolutamide)

+

tezacaftor/ ivacaftor

1 interaction

Caution Advised

darolutamide + tezacaftor/ ivacaftor

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. tezacaftor/ivacaftor levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• ticagrelor
Nubeqa (darolutamide)

+

ticagrelor

1 interaction

Caution Advised

darolutamide + ticagrelor

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. ticagrelor levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• tofacitinib
Nubeqa (darolutamide)

+

tofacitinib

1 interaction

Caution Advised

darolutamide + tofacitinib

caution advised: combo may decr. tofacitinib levels, efficacy (hepatic metab. induced)

• tolvaptan
Nubeqa (darolutamide)

+

tolvaptan

1 interaction

Caution Advised

darolutamide + tolvaptan

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. tolvaptan levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• topiramate
Nubeqa (darolutamide)

+

topiramate

1 interaction

Caution Advised

darolutamide + topiramate

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• toremifene
Nubeqa (darolutamide)

+

toremifene

1 interaction

Caution Advised

darolutamide + toremifene

caution advised: combo may decr. toremifene levels, efficacy (hepatic metab. induced)

• trazodone
Nubeqa (darolutamide)

+

trazodone

1 interaction

Caution Advised

darolutamide + trazodone

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• treosulfan
Nubeqa (darolutamide)

+

treosulfan

1 interaction

Caution Advised

darolutamide + treosulfan

caution advised: combo may incr. risk of seizures (additive effects)

• trimethoprim
Nubeqa (darolutamide)

+

trimethoprim

1 interaction

Caution Advised

darolutamide + trimethoprim

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• tucatinib
Nubeqa (darolutamide)

+

tucatinib

1 interaction

Caution Advised

darolutamide + tucatinib

caution advised: combo may incr. darolutamide levels, risk of adverse effects (hepatic metab. inhibited, P-gp-mediated transport inhibited)

• uridine triacetate
Nubeqa (darolutamide)

+

uridine triacetate

1 interaction

Caution Advised

darolutamide + uridine triacetate

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (gut P-gp-mediated transport possibly inhibited)

• vaborbactam
Nubeqa (darolutamide)

+

vaborbactam

1 interaction

Caution Advised

darolutamide + vaborbactam

caution advised: combo may decr. darolutamide levels, efficacy (P-gp-mediated transport possibly induced)

• valbenazine
Nubeqa (darolutamide)

+

valbenazine

1 interaction

Caution Advised

darolutamide + valbenazine

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• valproic acid
Nubeqa (darolutamide)

+

valproic acid

1 interaction

Caution Advised

darolutamide + valproic acid

caution advised if seizure disorder use: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• vandetanib
Nubeqa (darolutamide)

+

vandetanib

1 interaction

Caution Advised

darolutamide + vandetanib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• vanzacaftor/tezacaftor/deutivacaftor
Nubeqa (darolutamide)

+

vanzacaftor/ tezacaftor/ deutivacaftor

1 interaction

Caution Advised

darolutamide + vanzacaftor/ tezacaftor/ deutivacaftor

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. vanzacaftor/tezacaftor/deutivacaftor levels, efficacy (P-gp-mediated transport possibly inhibited; hepatic metab. induced)

• velpatasvir
Nubeqa (darolutamide)

+

velpatasvir

1 interaction

Caution Advised

darolutamide + velpatasvir

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. velpatasvir levels, efficacy (gut P-gp-mediated transport inhibited; hepatic metab. induced)

• vemurafenib
Nubeqa (darolutamide)

+

vemurafenib

1 interaction

Caution Advised

darolutamide + vemurafenib

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (P-gp-mediated transport inhibited)

• verapamil
Nubeqa (darolutamide)

+

verapamil

1 interaction

Caution Advised

darolutamide + verapamil

caution advised: combo may incr. darolutamide levels, risk of adverse effects; may decr. verapamil levels, efficacy (P-gp-mediated transport inhibited; hepatic metab. induced)

• vigabatrin
Nubeqa (darolutamide)

+

vigabatrin

1 interaction

Caution Advised

darolutamide + vigabatrin

caution advised: combo may alter seizure control (antagonistic effects, darolutamide may decr. seizure threshold)

• voclosporin
Nubeqa (darolutamide)

+

voclosporin

1 interaction

Caution Advised

darolutamide + voclosporin

caution advised: combo may decr. voclosporin levels, efficacy; may incr. darolutamide levels, risk of adverse effects, especially if also combined w/ strong CYP3A4 inhibitor (hepatic metab. induced; P-gp-mediated transport inhibited)

• vonoprazan
Nubeqa (darolutamide)

+

vonoprazan

1 interaction

Caution Advised

darolutamide + vonoprazan

caution advised: combo may decr. vonoprazan levels, efficacy (hepatic metab. induced)

• voxelotor
Nubeqa (darolutamide)

+

voxelotor

1 interaction

Caution Advised

darolutamide + voxelotor

caution advised: combo may decr. voxelotor levels, efficacy (hepatic metab. induced)

• xanomeline
Nubeqa (darolutamide)

+

xanomeline

1 interaction

Caution Advised

darolutamide + xanomeline

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects (gut P-gp-mediated transport possibly inhibited)

• zanubrutinib
Nubeqa (darolutamide)

+

zanubrutinib

1 interaction

Caution Advised

darolutamide + zanubrutinib

caution advised: combo may decr. zanubrutinib levels, efficacy (hepatic metab. induced)

• zonisamide
Nubeqa (darolutamide)

+

zonisamide

1 interaction

Caution Advised

darolutamide + zonisamide

if also combined w/ strong CYP3A4 inhibitor, caution advised: combo may incr. darolutamide levels, risk of adverse effects; may alter seizure control (P-gp-mediated transport possibly inhibited; antagonistic effects, darolutamide may decr. seizure threshold)